
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc. has demonstrated a promising therapeutic profile for its bifunctional antibody, ficerafusp alfa, particularly in its combination with Keytruda, showing a progression-free survival (mPFS) of 9.9 months and an overall survival (mOS) of 21.3 months. This performance is notably superior to the outcomes observed with Keytruda alone or in combination with chemotherapy, where lower overall response rates (ORR) of 19.1% and 38.0% respectively were reported. Given these strong clinical results, the prospect of ficerafusp alfa as a transformative treatment option points to a favorable growth trajectory for Bicara Therapeutics's stock.
Bears say
Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, which aligns closely with prior estimates of $0.51 per share, indicating ongoing financial challenges. Key risks impacting the company's outlook include potential negative clinical results for the pipeline candidate ficerafusp alfa, delays in progressing it into registrational trials, and the possibility of not obtaining regulatory approvals in a timely manner. Additionally, the increasing competition in the bispecific antibody space and concerns regarding long-term dilution pose further threats to the company’s financial stability.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares